NYSE · Financial Statements

Thermo Fisher Scientific Inc (TMO) Revenue, Earnings & Financial Statements

$693.11 NYSE: TMO Market Cap $256.81B

Data as of Nov 16, 2026 (intraday, delayed) · Statements through the quarter ended Jun 2026 · Source: Financial Modeling Prep (methodology)

Thermo Fisher Scientific Inc most recently reported annual revenue of $44.6B, net profit of $6.7B. Revenue grew at an average annual rate of 6.7% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Thermo Fisher Scientific Inc: Revenue rose from $18.3B in 2016 to $44.6B in 2025, a change of +143.8% over 9 years; net profit was positive in all 10 reported years; operating margin moved from 15.6% to 18.2%, a shift of +2.6 percentage points; the most recent year shows net profit of $6.7B.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$18.3B$20.9B$24.4B$25.5B$32.2B$39.2B$44.9B$42.9B$42.9B$44.6B
Operating Expenses$15.4B$17.7B$20.5B$21.3B$24.3B$28.9B$36.4B$35.4B$35.2B$36.4B
Operating Profit$2.9B$3.3B$3.9B$4.3B$7.9B$10.3B$8.5B$7.4B$7.7B$8.1B
Operating Margin15.6%15.6%15.9%16.7%24.5%26.3%19.0%17.4%17.9%18.2%
Other Income−$835.0M−$838.0M−$610.0M−$189.0M−$670.0M−$1.5B−$862.0M−$1.2B−$667.0M−$842.0M
Interest$470.0M$592.0M$667.0M$676.0M$553.0M$536.0M$726.0M$1.5B$1.7B$1.4B
Depreciation$1.8B$2.0B$2.3B$2.3B$2.3B$2.6B$3.4B$3.4B$3.1B$2.8B
Profit Before Tax$2.0B$2.4B$3.3B$4.1B$7.2B$8.8B$7.7B$6.2B$7.0B$7.3B
Tax rate (%)-0.1%8.3%9.9%9.2%11.8%12.6%9.2%4.5%9.4%7.5%
Net Profit$2.0B$2.2B$2.9B$3.7B$6.4B$7.7B$7.0B$6.0B$6.3B$6.7B
EPS$5.09$5.59$7.24$9.17$15.98$19.46$17.64$15.45$16.53$17.74

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$10.6B$10.9B$10.3B$10.5B$10.6B$11.4B$10.4B$10.9B$11.1B$12.2B$11.0B$12.0B
Operating Expenses$8.6B$8.9B$8.6B$8.8B$8.7B$9.1B$8.5B$8.9B$9.2B$9.9B$9.1B$9.9B
Operating Profit$2.0B$2.0B$1.7B$1.8B$1.9B$2.3B$1.8B$1.9B$1.9B$2.3B$1.9B$2.1B
Operating Margin18.7%18.3%16.6%16.7%18.1%19.9%17.8%17.7%17.5%18.9%16.9%17.4%
Interest$393.0M$444.0M$363.0M$421.0M$424.0M$384.0M$303.0M$404.0M$347.0M$365.0M$354.0M$401.0M
Profit Before Tax$1.7B$1.7B$1.6B$1.7B$1.7B$2.0B$1.6B$1.7B$1.8B$2.1B$1.7B$1.9B
Tax rate (%)3.0%7.7%17.4%7.6%5.7%7.6%5.9%5.4%11.3%7.2%4.0%8.7%
Net Profit$1.7B$1.6B$1.3B$1.5B$1.6B$1.8B$1.5B$1.6B$1.6B$2.0B$1.7B$1.7B
EPS$4.42$4.20$3.46$4.04$4.24$4.78$3.98$4.28$4.27$5.21$4.43$4.68

Over the 10 years reported for Thermo Fisher Scientific Inc, borrowings increased from $16.6B in 2016 to $39.4B in 2025, cash stood at $9.9B in the latest year, shareholders' equity was $445.0M, current assets covered current liabilities 1.89 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$45.9B$56.7B$56.2B$58.4B$69.1B$95.1B$97.2B$98.7B$97.3B$110.3B
Current Assets$7.0B$9.4B$10.6B$11.9B$22.0B$20.1B$25.2B$24.6B$22.1B$28.7B
Cash$786.0M$1.3B$2.1B$2.4B$10.3B$4.5B$8.5B$8.1B$4.0B$9.9B
Inventory$2.2B$3.0B$3.0B$3.4B$4.0B$5.1B$5.6B$5.1B$5.0B$5.4B
Receivables$3.0B$3.9B$4.6B$5.0B$6.5B$8.9B$9.4B$9.7B$9.6B$10.6B
Fixed Assets$2.6B$4.0B$4.2B$5.4B$6.7B$9.9B$10.9B$11.0B$10.8B$10.6B
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$37.0M$34.0M$53.0M$35.0M$65.0M$73.0M$155.0M$59.0M$2.1B$253.0M
Other Assets$21.3B$25.3B$25.3B$25.7B$26.0B$41.9B$41.2B$44.0B$45.9B$49.4B
Total Liabilities$24.4B$31.3B$28.6B$28.7B$34.5B$54.1B$53.0B$51.9B$47.6B$56.8B
Current Liabilities$4.9B$7.0B$6.1B$6.2B$10.3B$13.4B$17.0B$14.0B$13.3B$15.2B
Borrowings$16.6B$21.0B$19.0B$18.5B$22.5B$36.3B$36.1B$36.4B$32.8B$39.4B
Other Liabilities$7.7B$10.2B$9.7B$10.2B$12.0B$17.8B$16.9B$15.5B$14.9B$17.4B
Equity$415.0M$428.0M$432.0M$434.0M$437.0M$439.0M$441.0M$442.0M$444.0M$445.0M
Reserves$21.5B$25.4B$27.6B$29.7B$34.5B$40.8B$44.0B$46.7B$49.6B$53.4B

For Thermo Fisher Scientific Inc, operating cash flow was positive in 10 of 10 reported years; free cash flow in the latest year was $6.3B; free cash flow was positive in 10 of 10 years; financing activities used $2.9B in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$3.2B$4.0B$4.5B$5.0B$8.3B$9.5B$9.2B$8.4B$8.7B$7.8B
Investing Cash Flow−$6.0B−$8.2B−$2.0B−$2.4B−$3.0B−$24.5B−$4.4B−$6.6B−$7.2B−$5.6B
Financing Cash Flow−$1.2B−$753.0M−$415.0M−$2.1B−$1.5B−$1.9B−$3.0B−$2.9B−$3.8B−$2.9B
Net Cash Flow$334.0M$550.0M$756.0M$305.0M$7.9B−$5.8B$4.0B−$440.0M−$4.1B$5.8B
Free Cash Flow$2.7B$3.5B$3.8B$4.0B$6.8B$7.0B$6.9B$6.9B$7.3B$6.3B

Valuation & Return Ratios

MetricValue
PEG Ratio3.73
EV / EBITDA25.36
FCF Yield3.05%
Quick Ratio1.41
Interest Coverage5.54
Return 1Y21.12%
Return 3Y53.95%
Return 5Y14.61%

Thermo Fisher Scientific Inc (TMO) financials — frequently asked questions

What is Thermo Fisher Scientific Inc's annual revenue?

Thermo Fisher Scientific Inc (TMO) reported annual revenue of $44.6B in its most recent fiscal year.

What is Thermo Fisher Scientific Inc's net profit?

Thermo Fisher Scientific Inc (TMO) reported net profit of $6.7B in its most recent fiscal year.

What is TMO EV/EBITDA?

Thermo Fisher Scientific Inc's enterprise value to EBITDA (EV/EBITDA) ratio is 25.36.

Revenue and earnings of other Medical - Diagnostics & Research stocks

DHR revenue $24.6BIDXX revenue $4.3BA revenue $6.9BWAT revenue $3.2BIQV revenue $16.3BNTRA revenue $2.3BMTD revenue $4.0BILMN revenue $4.3BLH revenue $14.0BDGX revenue $11.0BAll Medical - Diagnostics & Research stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNYSE High ROE StocksAll stock screens
TMO Overview TMO Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.